Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic lymphocytic leukemia.

M J Keating1

  • 1Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

Seminars in Oncology
|November 24, 1999
PubMed
Summary
This summary is machine-generated.

Recent advances in chronic lymphocytic leukemia (CLL) research highlight new diagnostic markers and treatments. Novel therapies, including purine analogs and monoclonal antibodies like rituximab, are improving patient prognosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.

Leukemia·2017
Same author

ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2).

Blood cancer journal·2016
Same author

New Agents and Strategies in CLL Treatment.

Leukemia & lymphoma·2016
Same author

Long-Term Results of CAP Therapy in Chronic Lymphocytic Leukemia.

Leukemia & lymphoma·2016
Same author

Adhesion of B-Cell Chronic Lymphocytic Leukemia Cells to Marrow Stromal Cells is Mediated by α4β1 but not β2αL Integrin: MSC also Prevent Apoptosis of B-CLL Cells.

Hematology (Amsterdam, Netherlands)·2016
Same author

Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.

Leukemia·2016
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Chronic lymphocytic leukemia (CLL) research has seen significant recent interest.
  • CLL diagnosis involves differentiating mature B-cell variants using immunophenotype and morphology.
  • Cytogenetic abnormalities, particularly in chromosomes 11 and 17, are crucial for prognosis.

Purpose of the Study:

  • To review recent advancements in the understanding and treatment of chronic lymphocytic leukemia (CLL).
  • To discuss emerging prognostic factors and novel therapeutic strategies in CLL management.

Main Methods:

  • Review of immunophenotype studies and morphology for CLL diagnosis and variant identification.
  • Analysis of cytogenetic abnormalities and their prognostic significance.

Related Experiment Videos

  • Evaluation of immune dysregulation, apoptosis markers (bcl2, bax), and prognostic factors (beta2-microglobulin, soluble CD23).
  • Assessment of novel therapeutic agents, including purine analogs, monoclonal antibodies (rituximab, Campath-1H), and stem cell transplantation.

    • Main Results:

    • Purine analogs (fludarabine, 2-chlorodeoxyadenosine) show high activity in CLL treatment.
    • Monoclonal antibodies rituximab (anti-CD20) and Campath-1H (anti-CD52) demonstrate significant efficacy, especially in blood and bone marrow.
    • Abnormalities in bcl2 and bcl2:bax ratios are common, indicating apoptosis dysregulation.

    Conclusions:

    • Emerging prognostic factors and novel treatments are significantly altering the therapeutic landscape for CLL.
    • The development of purine analogs and monoclonal antibodies represents a major shift in CLL management.
    • Further exploration of stem cell transplantation modalities continues.